Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of cryoablation combined
with pd-1 antibody immunotherapy (Camrelizumab) and anti-angiogenesis therapy (Apatinib) in
patients with advanced hepatocellular carcinoma (HCC).